Tofacitinib em Artrite Psoriásica: Sinais e Sintomas e Qualidade de Vida Relacionada à Saúde em dois Estudos Randomizados de Fase 3
J Eur Acad Dermatol Venereol 2020;34:2809–2820.Considering the multi-domain nature of PsA, effective treatments must demonstrate efficacy across a range of clinical and patient-reported outcomes. Dermatologic symptoms often precede rheumatic manifestations in people with PsA, typically by 10 years. Tofacitinib demonstrated significant improvements across a range of outcomes including burdensome dermatologic symptoms. This post hoc analysis included data from two double-blind, Phase 3 studies in patients with active PsA and an inadequate resp...
Segurança e Eficácia de Tofacitinib em Pacientes com Artrite Psoriática Ativa: Análise Provisória de OPAL Balance, um Estudo Aberto de Extensão a Longo Prazo
Rheumatol Ther 2020 doi.org/10.1007/s40744-020-00209-4This 3-year, open-label, LTE study follows PsA patients previously treated in pivotal studies OPAL Broaden and OPAL Beyond. It demonstrates maintained safety and efficacy of tofacitinib up to 36 and 30 months, respectively. No new safety concerns are highlighted. Previous P3 studies, OPAL Broaden and OPAL Beyond, demonstrated safety and efficacy of 5mg and 10mg tofacitinib BID in PsA. These patients rolled over to OPAL Balance for a period of 36 months. 686 participants were used in this interim...